Ethyl Everninate

Ethyl Everninate

SCHEMBL1640418

CCOC(=O)c1c(C)cc(OC)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 1.00
HPGD P15428 3/20 1.00
TDP1 Q9NUW8 2/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
NR1H2 P55055 1/20 0.64
NR1H3 Q13133 1/20 0.64
KMT2A Q03164 3/20 0.63
POLB P06746 3/20 0.63
L3MBTL1 Q9Y468 1/20 0.59
ACHE P22303 1/20 0.53
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA7 P43166 2/20 0.51
CA9 Q16790 2/20 0.51
CA14 Q9ULX7 2/20 0.51
USP2 O75604 2/20 0.51
KDM4E B2RXH2 2/20 0.50
MAPK1 P28482 3/20 0.49
ALDH1A1 P00352 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Everninate SCHEMBL31233848 1.00 CYP3A4 (1.00) CYP3A4HPGDTDP1SMN1; SMN2NR1H2
SCHEMBL17779160 0.85 CYP3A4 (0.74) CYP3A4HPGDTDP1SMN1; SMN2NR1H2
Orsellinic Acid, Ethyl Ester SCHEMBL1648471 0.84 CYP3A4 (1.00) CYP3A4HPGDTDP1SMN1; SMN2NR1H2
SCHEMBL950536 0.84 CYP3A4 (1.00) CYP3A4HPGDTDP1SMN1; SMN2KMT2A
SCHEMBL10362928 0.83 HPGD (0.71) CYP3A4HPGDTDP1SMN1; SMN2NR1H2
SCHEMBL4106403 0.83 CYP3A4 (0.71) CYP3A4HPGDTDP1SMN1; SMN2NR1H2
SCHEMBL2580855 0.83 CYP3A4 (0.70) CYP3A4HPGDTDP1SMN1; SMN2NR1H2
SCHEMBL12587021 0.81 CYP3A4 (0.68) CYP3A4HPGDTDP1SMN1; SMN2NR1H2
SCHEMBL12770781 0.81 CYP3A4 (0.68) CYP3A4HPGDTDP1SMN1; SMN2NR1H2
SCHEMBL12552740 0.81 CYP3A4 (0.74) CYP3A4HPGDTDP1SMN1; SMN2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114994123-B Method and device for testing thermal stability of substance 江苏中烟工业有限责任公司 2024-11-19 CN disclosed
CN-114994123-A Method and device for testing thermal stability of substance 江苏中烟工业有限责任公司 2022-09-02 CN disclosed
CN-106397207-B Tree ketonic acid A structural analogue, composition thereof and application thereof in medicines 贵州医科大学 2020-12-08 CN disclosed
CN-110563690-A Tree ketonic acid A structural analogue, composition thereof and application thereof in medicines 贵州医科大学 2019-12-13 CN disclosed
US-9890351-B2 Encapsulates THE PROCTER & GAMBLE COMPANY (US) 2018-02-13 US disclosed
EP-2741731-B1 ENCAPSULATES PROCTER & GAMBLE (US) 2017-05-17 EP disclosed
EP-2308861-B1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS EISAI R&D MAN CO LTD (JP) 2017-03-01 EP disclosed
US-8889614-B2 Encapsulates THE PROCTER & GAMBLE COMPANY (US) 2014-11-18 US disclosed
EP-2468239-B1 Encapsulates PROCTER & GAMBLE INTERNAT OPERATIONS SA (CH) 2013-09-18 EP disclosed
US-20130196987-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS EISAI CO., LTD. (JP) 2013-08-01 US disclosed
US-7572805-B2 Pyrrolo(oxo)isoquinolines as 5HT ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-11 US disclosed
EP-1778225-A2 PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS Bristol-Myers Squibb Company (US) 2007-05-02 EP disclosed
US-7005440-B1 Therapeutic uses of tri-aryl acid derivatives AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2006-02-28 US disclosed
WO-2006019886-A2 PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-02-23 WO disclosed
US-20060014777-A1 Pyrrolo(oxo)isoquinolines as 5HT ligands BRISTOL-MYERS SQUIBB COMPANY 2006-01-19 US disclosed
US-6900340-B2 Preparation of isocoumarin derivatives and intermediates for the synthesis thereof MERCIAN CORPORATION (JP) 2005-05-31 US disclosed
US-20040102639-A1 Preparation of isocoumarin derivatives and intermediates for the synthesis thereof MERCIAN CORPORATION (JP) 2004-05-27 US disclosed
EP-1364947-A1 PREPARATION OF ISOCOUMARIN DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF Mercian Corporation (JP) 2003-11-26 EP disclosed
EP-1177176-A1 TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS Aventis Pharma Deutschland GmbH (DE) 2002-02-06 EP disclosed
WO-2000064876-A1 TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196987-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS FLT4, VEGFA, FLT1 CYP3A4 1158/4885HPGD 333/4885TDP1 3097/4885
US-20040102639-A1 Preparation of isocoumarin derivatives and intermediates for the synthesis thereof IDH1, IDH3A, IDH2 CYP3A4 73/4885HPGD 76/4885TDP1 4756/4885
US-20060014777-A1 Pyrrolo(oxo)isoquinolines as 5HT ligands HTR2B, OPRD1, HTR1B CYP3A4 1738/4885HPGD 2536/4885TDP1 3311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.